Injectable Drug Delivery Resources

  1. Lyophilized Products Are On The Rise: What You Need To Know 2/18/2022

    There is increased demand for lyophilization services in the manufacturing of new biologic drugs and injectable formulations as well as in change of formulation presentation.

  2. Delivering The Promise Of Gene Therapy 1/22/2024

    Gene therapies rely on efficient, precise methods of delivering genetic material. Examine how combining polymeric nanoparticles with CRISPR therapies is increasing the potential for improved treatment.

  3. Accelerating Gene Therapy With HITSCAN Platform 4/16/2025

    Battelle’s HIT SCAN™ platform accelerates gene therapy by rapidly designing, screening, and optimizing nanoparticle drug delivery systems using high-throughput robotics and machine learning.

  4. Why It Is Never Too Early To Consider Tungsten Interactions 3/2/2023

    A key challenge to sensitive biotechnological or biologic drugs, especially proteins, is the potential presence of tungsten and tungsten oxides from the syringe forming process.

  5. Computational Modeling Of Injection-Related Tissue Responses 6/15/2022

    Optimizing delivery along with the formulation is the key to successful clinical outcomes. Research is necessary to understand the relationship between body morphology, injection force, and needle length.

  6. Design Success Combined With Expertise In Testing And Raw Material Selection

    Learn more about improvements and optimized benefits across the packaging attributes required for performance, quality, and safety of the packaging and delivery of lyophilized drug products.

  7. Evaluation And Identification Of Subvisible Particulate Matter In Injections

    Review the scopes of USP chapters <787> and <788>. Both chapters address injections and have the same regulatory requirements according to their nominal volumes for subvisible PM.

  8. Maintaining Superior Viral Vector Recovery In Cell And Gene Therapy Applications 9/3/2024

    A study assessing the stability of vials aimed to determine if the vial material had any influence on the viral titer and particle counts of the AAV serotypes.

  9. Viral Vector Based Gene Therapy Drug Products: The Right Primary Container 5/20/2024

    Explore the major considerations for an ideal primary container for viral vector-based gene therapy drug products and the existing and new solutions in this space.

  10. A Robust Extractables Data Package Helps Drive Patient Safety 10/1/2024

    Complex drug product formulations are more common, so it is imperative to have a deeper knowledge of extractables to understand risks associated with potential interactions between packaging and product.